Search 

My company Bertil Allard Holding have interest some companies in Life Science. The major investment is in Hörsam ( www.horsam.se ) but I am also a boardmember of Phoniro ( www.phoniro.se ). I have also involvment in Puls ( www.pulsinvest.se ) and the very new Brorsson Innovation ( wwww.brorssoninnovation.se ). My former company, today owned by my youngest son was Camp Scandinavia www.camp.se My main area of interest in Life Science relates to rehabilitation but in a wide aspect.

Etteplan supports Medtech companies with design and development. ISO 13485 certified our 70 consultant engineers and designers help large and small companies develop products in all MDD Classes I-III from idea to production. Offices are located in Stockholm, Uppsala, Halmstad, Lund, Copenhagen and Helsinki offering the following engineering skills: Usability, Innovation Workshops, Industrial Design, Mechanical Engineering, Hardware/Software Development, Project Management, Regulatory Affairs and Documentation

Company specialized in wireless and mobile solutions for monitoring, alarn and control wiithin health care and security markets.

We focus on eldercare and we already have thousands of users and have entered the growth phase. Major distribution deals have been signed in UK, NL, FR, SE, FI and will shortly be in US.

Looking to raise a total of 3 M in funding for the expansion and rapid growth.

Our leading product is the Vega GPS global solution with the wearable watch providing answers to 3 major challenges:

- protection always available

- always know where a person/wearer is

- interact with the users

eWELL Oy is a consultancy company specialized for the health and social care sector ICT and service solution innovation development and networks. Kalevi Virta has a long experience from the Finnish eco system, he has coordinated several major funding and development programmes and has excellent connections to different private companies, service providers and research organizations.

Synergus is a MedTech Consulting Company in Reimbursement & Health Economics and Quality & Regulatory

Unisensor is seeking investors for the development, clinical evaluation and launch of a new instrument for antibiotic susceptibility testing.

Sepsis (blood poisoning) is a serious medical condition that in US alone kills more than 100,000 annually, surpassing the number of deaths from acute myocardial infarction (AMI), stroke, or cancer. Once detected, it is paramount to initiate the proper antibiotic therapy as soon as possible, since survival chance decrease by the hour. In addition septicaemia patients is a substantial economic burden to the hospital – according to one source up to 50.000 USD per patient. Traditional AST typically takes from 15-30 hours, and Unisensor has shown that this can be decreased to less than one hour by using our patented technology. This will not only increase the survival chance and reduce the costs, but also have the societal benefit, that the emergence of multi-resistant bacteria is reduced due to the earlier usage of the proper narrow-band antibiotic therapy.

To finance the instrument development, clinical evaluation and initial sales and marketing activities Unisensor is seeking investors to enter into a joint venture or or other financial collaboration or partnership.